Dose timing of d-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale

Contemporary Clinical Trials

Volumn 43, Issue , 2015, Pages 223-230

  Hofmann, Stefan G ^a   Carpenter, Joseph K ^a   Otto, Michael W ^a   Rosenfield, David ^b   Smits, Jasper A J ^c   Pollack, Mark H ^d  

^a BOSTON UNIVERSITY   (United States)

^b SOUTHERN METHODIST UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cognitive behavioral therapy; D cycloserine; Exposure therapy; Social anxiety disorder; Social phobia

Indexed keywords

CYCLOSERINE; PLACEBO; HYDROCORTISONE;

APPRAISAL OF SOCIAL CONCERNS; ARTICLE; COGNITIVE THERAPY; CONSENSUS SLEEP DIARY; CONTROLLED STUDY; DRUG EFFICACY; FEAR; FEMALE; HEART RATE; HUMAN; LIEBOWITZ SOCIAL ANXIETY SCALE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NEO FIVE FACTOR INVENTORY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PITTSBURGH SLEEP QUALITY INDEX; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL DISTRESS ASSESSMENT; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; REMISSION; SALIVA ANALYSIS; SCREENING; SKIN CONDUCTANCE; SOCIAL ANXIETY QUESTIONNAIRE FOR ADULTS; SOCIAL PHOBIA; SOCIAL PHOBIC DISORDERS SEVERITY AND CHANGE FORM; SUBJECTIVE UNITS OF DISTRESS SCALE; SUBTLE AVOIDANCE FREQUENCY EXAMINATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANXIETY DISORDERS; CHEMISTRY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; IMPLOSIVE THERAPY; METHODOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROCEDURES; SALIVA; SEVERITY OF ILLNESS INDEX; SLEEP;

ANXIETY DISORDERS; COMBINED MODALITY THERAPY; CYCLOSERINE; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; HYDROCORTISONE; IMPLOSIVE THERAPY; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; SALIVA; SEVERITY OF ILLNESS INDEX; SLEEP;

EID: 84932631518     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.06.015     Document Type: Article

References (58)

1. Hofmann S.G., Smits J.A.J. Cognitive-behavioral therapy for adult anxiety disorders: a meta analysis of randomized placebo-controlled trials. J. Clin. Psychiatry 2008, 69:621-632.
2. Hofmann S.G., Sawyer A.T., Korte K., Smits J.A.J. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int. J. Cogn. Ther. 2009, 2:160-175.
3. Otto M.W., Smits J.A.J., Reese H.E. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin. Psychol. Sci. Pract. 2005, 12:72-86.
4. Myers K.M., Davis M. Behavioral and neural analysis of extinction: a review. Neuron 2002, 36:567-584.
5. Hofmann S.G., Wu Q.J., Boettcher H. D-cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol. Mood Anxiety Disord. 2013, 3:11.
6. Hofmann S.G., Meuret A.E., Smits J.A.J., et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry 2006, 63:298-304.
7. Guastella A.J., Richardson R., Lovibond P.F., et al. A randomized controlled trial of the effect of D-cycloserine on enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry 2008, 63:544-549.
8. Ressler K.J., Rothbaum B.O., Tannenbaum L., et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch. Gen. Psychiatry 2004, 61:1136-1144.
9. Otto M.W., Tolin D.F., Simon N.M., et al. Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol. Psychiatry 2010, 67:365-370.
10. Guastella A.J., Dadds M.R., Lovibond P.F., Mitchell P., Richardson R. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J. Psychiatr. Res. 2007, 41:466-471.
11. Guastella A.J., Lovibond P.F., Dadds M.R., Mitchell P., Richardson R. A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav. Res. Ther. 2007, 45:663-672.
12. Hofmann S.G., Smits J.A.J., Rosenfield D., et al. D-cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am. J. Psychiatry 2013, 170:751-758.
13. Litz B.T., Salters-Pedneault K., Steenkamp M.M., et al. A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. J. Psychiatr. Res. 2012, 46:1184-1190.
14. Tart C., Handelsman P., Smits J.A.J., et al. Augmentation of exposure therapy with post-session administration of D-cycloserine. J. Psychiatr. Res. 2013, 47:168-174.
15. Rothbaum B.O., Price M., Jovanovic T., et al. A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. Am. J. Psychiatr. 2014, 171:640-648.
16. Smits J.A.J., Rosenfield D., Hofmann S.G., et al. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J. Psychiatr. Res. 2013, 47:1455-1461.
17. Smits J.A.J., Rosenfield D., Otto M.W., et al. D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: Evidence from the treatment of height phobia. Biol. Psychiatry 2013, 73:1054-1058.
18. Hofmann S.G. D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress. Anxiety 2014, 31:175-177.
19. Lee J.L., Milton A.L., Everitt B.J. Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J. Neurosci. 2006, 26:10051-10056.
20. Psychiatric Association American Diagnostic and statistical manual of mental disorders 2013, (Washington, DC.). 5th ed.
21. Liebowitz M.R. Social phobia. Mod. Probl. Pharmacopsychiatry 1987, 22:141-173.
22. Zeidan M., Lebron-Milad K., Milad M., et al. Test-retest reliability during fear acquisition and fear extinction in humans. CNS Neurosci. Ther. 2012, 18(4):313-317.
23. D'Souza D.C., Gil R., Cassello K., et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol. Psychiatry 2000, 47:450-462.
24. van Berckel B.N., Lipsch C., Timp S., et al. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 1997, 16:317-324.
25. Smits J.A.J., Rosenfield D., Powers M.B., et al. Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. Biol. Psychiatry 2014, 75:840-846.
26. Heimberg R.G., Horner K., Liebowitz M.R., et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol. Med. 1999, 29:199-212.
27. Safren S., Heimberg R.G., Horner K., Juster H., Schneier F.R., Liebowitz M.R. Factor structure of social fears: the Liebowitz Social Anxiety Scale. J. Anxiety Disord. 1999, 13:253-270.
28. Liebowitz M.R., Schneier F.R., Campeas R., et al. Phenelzine vs atenolol in social phobia. A placebo controlled comparison. Arch. Gen. Psychiatry 1992, 49:290-300.
29. Guy W. Clinical global impression. Manual for the ECDEU Assessment battery - revised 1970, 218-222. National Institute of Mental Health, Rockville, MD. W. Guy (Ed.).
30. Heimberg R.G., Liebowitz M.R., Klein D.F., et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch. Gen. Psychiatry 1998, 55:1133-1141.
31. Telch M.J., Lucas R.A., Smits J.A.J., Powers M.B., Heimberg R.G., Hart T. Appraisal of social concerns: a cognitive assessment instrument for social phobia. Depress. Anxiety 2004, 19:217-224.
32. Cuming S., Rapee R.M., Kemp N., Abbott M.J., Peters L., Gaston J.E. A self-report measure of subtle avoidance and safety behaviors relevant to social anxiety: development and psychometric properties. J. Anxiety Disord. 2009, 23:879-883.
33. Caballo V.E., Arias B., Salazar I.C., Irurtia M.J., Hofmann S.G. CISO-A Research Team. Psychometric properties of an innovative self-report measure: the Social Anxiety Questionnaire for Adults. Psychol. Assess. 2015, (in press).
34. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
35. Endicott J., Nee J., Harrison W., Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol. Bull. 1993, 29:321-326.
36. Wolpe J. Psychotherapy by reciprocal inhibition 1958, Stanford University Press.
37. Hayes S.A., Hope D.A., Heimberg R.G. The pattern of subjective anxiety during in-session exposures over the course of cognitive-behavioral therapy for clients with social anxiety disorder. Behav. Ther. 2008, 39:286-299.
38. Smits J.A.J., Hofmann S.G., Pollack M.H., et al. D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J. Consult. Clin. Psychol. 2013, 81:1100-1112.
39. Smits J.A.J., Powers M.B., Buxkamper R., Telch M.J. The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: a controlled investigation. Behav. Res. Ther. 2006, 44:1773-1785.
40. Smits J.A.J., Rosenfield D., McDonald R., Telch M.J. Cognitive mechanisms of social anxiety reduction: an examination of specificity and temporality. J. Consult. Clin. Psychol. 2006, 74:1203-1212.
41. Buysse D.J., Reynolds C.F., Monk T.H., et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28:193-213.
42. Zalta A., Dowd S., Pollack M.H., et al. Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress. Anxiety 2013, 30:1114-1120.
43. Carney C.E., Buysse D.J., Morin C.M., et al. The Consensus Sleep Diary: standardizing prospective sleep self-monitoring. Sleep 2012, 35:287-302.
44. Costa P.T., McCrae R.R. The five-factor model of personality and its relevance to personality disorders. J. Pers. Disord. 1992, 6:343-359.
45. Laukka P., Linnman C., Furmark T., et al. In a nervous voice: acoustic analysis and perception of anxiety in social phobics' speech. J. Nonverbal Behav. 2008, 32:195-214.
46. Pennebaker J.W., Francis M.E., Booth R.J. Linguistic Inquiry and Word Count (LIWC): a computerized text analysis program 2001, (Mahwah, NJ).
47. Andersson E., Hedman E., Enander J., et al. D-cycloserine vs placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: a randomized clinical trial. JAMA Psychiatry 2015 May 13, 10.1001/jamapsychiatry.2015.0546.
48. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
49. Brown T.A., Barlow D.H. Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5L): Lifetime Version. Client Interview Schedule 2014, Oxford University Press.
50. Devilly G.J., Borkovec T.D. Psychometric properties of the credibility/expectancy questionnaire. J. Behav. Ther. Exp. Psychiatry 2000, 31:73-86.
51. Enders C.K. Missing not at random models for latent growth curve analyses. Psychol. Methods 2011, 16:1-16.
52. Hamer R.M., Simpson P.M. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am. J. Psychiatry 2009, 166:639-641.
53. Mennin D.S., Fresco D.M., Heimberg R.G., Schneier F.R., Davies S.O., Liebowitz M.R. Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. J. Anxiety Disord. 2002, 16:661-673.
54. Ballenger J.C., Davidson J.R., Westenberg H.G., et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J. Clin. Psychiatry 1998, 59:54-60.
55. Singer J.D., Willett J.B. Applied longitudinal data analysis: methods for studying change and event occurrence 2003, Oxford University Press, New York.
56. Fournier J.C., DeRubeis R.J., Shelton R.C., Hollon S.D., Amsterdam J.D., Gallop R. Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J. Consult. Clin. Psychol. 2009, 77:775-787.
57. Snijders T.A.B., Bosker R.J. Standard errors and sample sizes for two-level research. J. Educ. Stat. 1993, 18:237-259.
58. Grillon C. D-cycloserine facilitation of fear extinction and exposure-based therapy might rely on lower-level, automatic mechanisms. Biol. Psychiatry 2009, 66:636-641.